Unknown PHASE1 INTERVENTIONAL 1-arm NCT05644392

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

An Open, Single-arm, Single-centre Clinical Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours That Have Failed at Least One Prior Systemic Therapy

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Conditions Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy

Interventions Cadonilimab Injection Regorafenib

Updated 4 times since 2023 Last updated: Dec 7, 2022 Started: Nov 25, 2022 Primary completion: Nov 25, 2025 Completion: Nov 25, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy and is currently ongoing. Tianjin Medical University Cancer Institute and Hospital leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Dec 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jan 2023 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

Nov 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tianjin Medical University Cancer Institute and Hospital

Data source: Tianjin Medical University Cancer Institute and Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China